MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Citarinostat

CAS No. : 1316215-12-9

MCE 站：Citarinostat

产品活性：Citarinostat (ACY241) 是第二代有效的，口服活性，高选择性的 HDAC6 抑制剂，IC₅₀ 为 2.6 nM (HDAC1，HDAC2，HDAC3 和 HDAC8 的 IC₅₀ 分别为 35 nM，45 nM，46 nM 和 137 nM)。Citarinostat 具有抗癌作用。

研究领域：Cell Cycle/DNA Damage  |  Epigenetics

作用靶点：HDAC

In Vitro: Citarinostat (ACY241; 0-3 μM; 24 hours; A2780 cells) treatment with 300 nM results in increased hyperacetylation of α-tubulin, consistent with inhibition of the tubulin deacetylase HDAC6. In contrast, hyperacetylation of histone H3, a target of Class I HDACs, is only observed at doses above 1 μM. Low exposures of Citarinostat result in selective inhibition of HDAC6, while higher exposures lead to inhibition of Class I HDAC isozymes.
The single agent viability IC₅₀ of Citarinostat (ACY241) ranged from 4.6-6.1 μM in A2780 and TOV-21G ovarian cancer and MDA-MD-231 breast cancer cells. Consistent with the viability assay, single agent Citarinostat modestly reduces proliferation at doses up to 3 μM without inducing apoptosis, while 10 μM of Citarinostat causes significant induction of apoptosis and completely suppresses proliferation.

In Vivo: Citarinostat (ACY241; 50 mg/kg; intraperitoneal injection; once daily for five days, followed by two days off; for 3 weeks; female athymic nude mice) significantly suppresses tumor growth in combination with NSC 125973.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Orally Active Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Trichostatin A  |  4-Phenylbutyric acid  |  Valproic acid  |  Entinostat  |  Sulforaphane  |  Romidepsin  |  RGFP966  |  Tasquinimod  |  Corin  |  Tacedinaline  |  Dacinostat  |  ITSA-1  |  SIS17  |  Tubastatin A Hydrochloride  |  WT-161  |  Givinostat hydrochloride monohydrate  |  Pyroxamide  |  BRD-6929  |  Bufexamac  |  HDAC8-IN-1  |  Scriptaid  |  Sinapinic acid  |  Apicidin  |  BML-210  |  M344  |  Droxinostat  |  HDACs/mTOR Inhibitor 1  |  CG347B

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。